Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Advanced Course on Metastatic EGFR-Mutant NSCLC

ESMO Advanced Course on Metastatic EGFR-Mutant NSCLC Banner 700x184 px
Start date
28 Oct 2016
End date
29 Oct 2016
Seoul, Korea, Republic of

This ESMO advanced course was created to update and inform clinicians on the latest developments in the understanding of the development of resistance to TKI therapies, the genetic origins of the resistance and the latest diagnostic and clinical developments enabling the clinical management of resistance in NSCLC patients.

ESMO advanced courses provide state-of-the-art lectures in an interactive setting, made possible by providing ample time for delegates to present questions to the course faculty members and through the inclusion in the programme of highly interactive workshops.

Learning Objectives

  • To understand the biology and role of EGFR and TKI’s (1st, 2nd, 3rd generation) in the management of NSCLC
  • To understand the development of resistance to TKI’s and the available treatment options
  • To understand the role of T790M in the development of resistance
  • To understand the utility of different diagnostic methods in identifying the resistance mechanism
  • To understand the importance of the multidisciplinary team and particularly the pathologist and radiologists in optimising diagnosis and selection of the most appropriate treatment options

Access the slides on OncologyPRO


The programme was designed for medical oncologists, clinical oncologists, organ specialists, radiation oncologists, surgeons, pathologists and other members of multidisciplinary teams managing NSCLC patients. This event has been accredited with 9 ESMO-MORA CME Points.

Download the programme


Chair: Rolf A. Stahel, Switzerland
Local Chair: Keunchil Park, South Korea


Conrad Hotel Seoul
10 Gukjegeumyung-ro (Yeouido) Yeongdeungpo-gu
Seoul, 07326
South Korea


AstraZeneca provided a sponsorship grant towards this independent Programme.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings